Company ProfilePremium

Cann Group Limited

Company Profile Analysis

Ticker: CAN.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cann Group Limited - Company showcase

Year Founded & Workforce

2014

Cann Group Limited logo

Cann Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cann Group Limited Overview

Cann Group was the first company in Australia to receive medicinal cannabis research and cultivation licences, in February and March 2017. It remains one of the country's few vertically integrated, GMP-certified producers of dried cannabis flower at industrial scale. Its core asset is a glasshouse cultivation and GMP manufacturing facility near Mildura, Victoria. It was built for about A$115–120m and designed for more than 12,500kg of dried flower a year, but it ran at roughly half of fitted capacity in FY26, producing 4.6 tonnes.

After a near-insolvency episode in 2024–25, the company completed a balance-sheet reset in December 2025. It discharged A$70.6m of National Australia Bank debt for A$15.3m, refinanced with a private credit fund and raised A$9.0m of equity. Revenue has nonetheless fallen for two years, to A$8.6m in FY26. The investment case now rests on export conversion (UK first, Germany next), utilisation of under-used GMP capacity, and possible strategic or M&A outcomes in a consolidating sector.


Company's own description

The FY26 announcements describe the business as follows (paraphrased). Cann aims to improve patients' lives by developing, producing and supplying innovative cannabis medicines. It operates a large-scale cultivation and GMP manufacturing facility with integrated research capability near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, plus bulk and white-label supply, it sells dried flower, oil, vape and edible medicinal cannabis products to customers in Australia and abroad (FY26 Results Announcement, 31 Aug 2026). Earlier boilerplate (FY25 to Nov 2025) also referred to active pharmaceutical ingredients, extracts and the Satipharm patent-protected capsule technology.

Independent characterisation

Cann is in practice a single-asset, cultivation-led medicinal cannabis manufacturer with an increasingly B2B mix. Revenue comes almost entirely from product sales: A$8.551m of A$8.563m in FY26. Services, mainly contract packing, contributed only A$0.012m in FY26, down from A$0.162m in FY25 (Appendix 4E Note 1).

The business model has moved through three phases:

2017–2021: a licence-holder and R&D platform. Revenue was negligible (A$0.56m in FY18), and Aurora-supplied product was used to serve the first patients.

2022–2024: a capex-heavy scale-up at Mildura funded by NAB construction debt. Revenue came from white-label oils, bulk and branded flower, alongside heavy losses.

2025–present: a restructured, cost-reset producer. Management has deliberately stepped back from low-margin white-label oil manufacturing and low-priced bulk channels to prioritise branded flower, B2B wholesale with minimum order quantities, and exports.

Revenue model mix (FY26, Appendix 4E and FY26 results)

Revenue typeFY26 AUD MnShare of revenueComment
Product sales: dried flower7.790%Botanitech (own-grown and curated), Mallee Bloom, bulk and white-label flower
Product sales: oils0.56%Legacy white-label and branded oils, being de-emphasised
Product sales: other (vapes, gummies, capsules)about 0.35 (derived residual)about 4%—
Services (contract packing)0.012<1%GMP contract packing and white-label capability
Total revenue from customer contracts8.563100%—
Other income (R&D tax incentive and grants; other)1.089—Not counted in revenue

Subscription and licensing revenue: none disclosed.

Value-chain position

Cann covers most of the value chain:

  • genetics and breeding, including in-house strains La Bomba Ese and Lazer Fuel (AGM 2025);

  • tissue culture and mother-stock management;

  • cultivation;

  • post-harvest work (drying, with a move to a GMP hang-dry process, trimming and irradiation);

  • GMP packing.

For formulated products, it has historically relied on third-party contract manufacturers such as IDT Australia. Downstream it sells to:

  • wholesalers and distributors (bulk);

  • brand owners (white label);

  • prescriber-pharmacy channels in Australia under the TGA framework (Special Access Scheme / Authorised Prescriber pathways);

  • export importers in the UK, New Zealand and, prospectively, Germany and the wider EU.

Customer types and end-markets

Domestic B2B wholesalers and distributors: the largest channel by volume in FY26. Three customers each exceeded 10% of revenue, up from one in FY25.

Domestic pharmacy and patient (B2C brand) channel: Botanitech and Mallee Bloom, including supply agreements with 11 Chemist Warehouse outlets in Queensland on an initial two-year term (TipRanks summary of ASX release).

Export importers: UK (A$1.0m in FY26, the first year), New Zealand (A$0.36m) and Germany. AMRadV irradiation-related licences were secured in Q3 FY26 to support German and EU distribution.

End-markets: prescribed medicinal cannabis for chronic pain, anxiety, sleep and other indications under physician supervision.

Strategy

Stated strategic themes (FY26 Results, AGM 2025, Q3–Q4 FY26 4Cs)

  1. A rebuilt balance sheet as a platform. The Chairman says FY26 rebuilt the balance sheet "to match the operating reset delivered in FY2025".

  2. Export-led growth. The UK is established; Germany and the EU are in progress, using GMP certification as European buyers increasingly require pharmaceutical-grade, GMP-produced flower.

  3. Strategic value of certified capacity. Management argues that global operators are competing to secure GMP-certified cultivation capacity, which re-rates the Mildura asset.

  4. Margin over volume. Cann is exiting low-priced bulk and white-label oils and prioritising Botanitech own-grown flower, Mallee Bloom and exclusive genetics.

  5. Cost discipline. The H2 exit run-rate of about A$12m sets the FY27 cost base.

  6. Strategic partnering and M&A. Management continues to explore partnerships and transactions amid sector consolidation, and flagged an update before 30 June 2026.

Initiatives in the last 24 months

InitiativeDateDetail / target
Debt restructure and recapitalisationOct–Dec 2025NAB debt of A$70.6m settled for A$15.3m; A$14.75m private credit facility; A$9.0m equity
Organisational restructureFY25–FY26Employee costs down 26% in FY26
R&D relocation to MilduraFY26Lower rent and overheads
GMP hang-dry transitionFY26Better terpene retention, lower microbial risk and export readiness
Rapid-drying technology trialFY26Shorter drying cycles, microbial control and export formats
Plant-density optimisation studyFY26Maximise yield per m²
Yield improvementFY25Wet-to-dry ratio raised from 7% to 13% (AGM 2025)
ERP and seed-to-sale migration to cloudH2 FY26Compliance and inventory control
QA/QC process reviewH2 FY26Export qualification
Inventory overhaulH2 FY26Legacy stock rationalised; new stocktake methodology
Mallee Bloom launchQ2 FY26Mid-price/premium Australian-grown brand
Gummies launchOct 2025New edible format
Chemist Warehouse supply (11 Queensland outlets)2,025Initial two-year term
UK export commencementQ3 FY26A$1.0m in FY26
German AMRadV licencesQ3 FY26Irradiation-licensing pathway for Germany
Convertible notes eliminated30 Jun – 3 Jul 2026Removes toxic-dilution overhang

Guidance and targets

FY27: no quantitative guidance. Management reports a "very strong start": unaudited July revenue was well ahead of the prior year and export revenue stayed strong in August. It expects a material increase in production volume and operating leverage based on forward orders.

Superseded FY26 targets: (AGM 2025): revenue of about A$17m, EBITDA of A$0.3–0.7m and production of 7.7 tonnes. Actuals were A$8.56m, -A$3.7m and 4.6 tonnes.

Medium-term targets: not publicly disclosed.

ESG commitments: none publicly disclosed.

Products & Services

The portfolio is organised by channel because there is only one reporting segment. Pricing is not publicly disclosed for any SKU. Management sensitivity: every A$0.10/gram price increase adds about A$0.8m a year to profitability at 8 tonnes of production (AGM 2025).

Brands (B2C)

Brand / productDescriptionTarget customerLaunch / latestNotes
Botanitech dried flower (own-grown)Cann-bred, Mildura-grown high-THC and balanced flower, multiple THC/CBD SKUsPrescribed patients via clinics and pharmaciesFirst in-house flower Mar 2022Own-grown Botanitech accounted for about 40% of 1H FY26 revenue (1H FY26 results). Revenue rose more than 100% YoY in FY25.
Botanitech curated rangeExternally sourced (imported or third-party) flower sold under the Botanitech brandPatients—Revenue fell 46% in 1H FY26 as Cann pivoted to own-grown
Botanitech oilsTHC/CBD oil formulationsPatients—Oils total A$0.5m in FY26
Botanitech vape cartridgesVape cartsPatientsProduct timeline 2023–2024Part of brand range (AGM 2025)
Botanitech / "Skylark" gummiesEdible formatPatientsOct 2025First edible format (AGM 2025)
INC ("It's Not Craft") flower rangeValue-oriented flower rangePrice-sensitive patientsBrand timeline 2022–2025Named in AGM 2025 product timeline
NRG flower rangeFlower rangePatientsBrand timelineNamed in AGM 2025 product timeline
Curated & VAL flower rangeValue/curated flowerPatientsBrand timelineNamed in AGM 2025 product timeline
Mallee BloomMid-price/premium, "Australian-owned and grown" flower brandPatients wanting domestic provenanceQ2 FY26, with new SKUs added by Q4 FY26Launched in response to demand for Australian-grown flower
Satipharm CBD capsulesPatent-protected gelatin-matrix capsule delivery technology for CBDPatients; international nutraceutical and medicinal marketsAcquired early 2021Still owned (1H FY26 boilerplate). Year-end inventory of "finished goods – capsules" was A$4.423m, though this label may be a legacy classification (see Section 6).

Enterprise (B2B)

OfferingDescriptionTarget customerNotes
Bulk dried flowerWholesale supply of trimmed dried flowerDomestic distributors and brand owners; export importersHighest B2B orders of FY26 came in Q3. Q1 FY26 was ahead of budget. Low-priced bulk is being deprioritised for margin.
White-label flowerFlower supplied under the customer's brand, with minimum order quantitiesBrand owners without cultivationNew white-label customers signed in FY25. New strains sought on an exclusive basis.
White-label oilsFormerly contract-manufactured oilsBrand ownersBeing exited because of low margins and stable demand (AGM 2025)
Contract packingGMP-compliant automated packing linesThird-party brandsFY26 service revenue was only A$12k
By-product monetisationTrim sold for extraction; small buds sold as a value rangeExtractors; value segmentAGM 2025
Export flower (UK)Dried flower meeting UK customer specificationsUK importers and distributorsA$1.0m in FY26, the first year
Export flower (NZ)Dried flowerNZ distributorsA$0.36m in FY26 versus A$0.06m in FY25
Export pathway (Germany / EU)Irradiated flower under AMRadV licences; non-irradiated formats in developmentGerman pharmacy-distribution importersPathway established. EU microbial specification work continues.

Genetics

Cann maintains a proprietary breeding programme. Two strains, La Bomba Ese and Lazer Fuel, were in full production as of November 2025. Tissue culture is used for disease-free mother stock (FY26 Results).

Financial Narrative

Sources: FY2025–FY2026 from the Appendix 4E FY26 (unaudited FY26). FY2022–FY2024 from S&P Global Market Intelligence via StockAnalysis.com (data updated 31 Aug 2026). All figures in A$ millions unless stated.

Margins (chartable, % of revenue from customer contracts)

Revenue CAGR FY2022–FY2026: about 7.5% a year (A$6.41m to A$8.56m).

Revenue CAGR FY2024–FY2026: about -25.4% a year, reflecting two years of decline from the FY24 peak.

Non-recurring items bridge (FY2026)

Source: FY26 Results Announcement.

Balance sheet (chartable)

Total debt in FY2026 comprises the private credit refinancing loan (A$15.356m, non-current), the R&D tax incentive advance (A$0.469m), chattel mortgages (A$0.011m) and convertible notes (A$0.551m, current, redeemed 3 Jul 2026).

Cash flow (chartable)

FY2024 and FY2023 investing cash flows also included proceeds from asset sales of A$3.68m and A$3.07m respectively, consistent with the Southern facility disposal.

Ratios (chartable)

Net debt / EBITDA: is not meaningful in any year because EBITDA was negative.

ROE for FY2025: is not meaningful because equity was negative.

FY2026 ROE and ROA: are inflated by the A$55.3m non-cash debt-forgiveness gain. On normalised NPAT of -A$14.7m, ROE would be about -51% and ROA about -28%.

Cash conversion cycle:

  • Days sales outstanding on trade receivables: about 19 days in FY2025 and about 19 days in FY2026.

  • Inventory days against direct production costs: about 196 days in FY2025 and about 456 days in FY2026.

  • A meaningful cash conversion cycle cannot be computed, because the cost base is mostly fixed employee and facility costs and inventory includes legacy holdings.

Commentary on trends, inflections and drivers

Revenue. Revenue peaked at about A$15.4m in FY2024, after the Mildura ramp-up and heavy white-label oil and bulk activity. It then fell 26.5% in FY2025 and 24.2% in FY2026. Management attributes the FY26 decline to persistent price pressure in domestic dried flower and a deliberate exit from low-priced bulk and low-margin white-label oil.

The FY26 figure is a significant miss against guidance:

October/November 2025: revenue of about A$17m (+50%) and EBITDA of +A$0.3m to +A$0.7m (AGM 2025).

February 2026: EBITDA breakeven targeted for H2.

April 2026: guidance cut to A$9.2–10.0m with an EBITDA loss.

Actual: revenue A$8.56m and normalised EBITDA -A$3.7m.

Management credibility on forecasting is therefore a material analytical issue.

Cost base. The cost reset is real and verifiable in the statutory accounts. Operating costs before depreciation fell from A$22.2m in FY25 to A$14.7m in FY26, including the inventory write-down. Within that:

  • direct production costs fell 55%;

  • employee costs fell 26%;

  • administration fell 12%;

  • D&A fell 21%, partly because of the impairments.

H2 FY26 operating costs before D&A, write-down and R&D were A$6.0m, against A$7.0m in H1. That implies an annualised run-rate of about A$12m. At revenue of about A$8.6m, Cann still needs either about 40% more revenue at constant margin, or a mix shift to exports and branded flower, to reach EBITDA breakeven.

Balance sheet. FY26 is the inflection year. Total debt fell from A$75.8m to A$16.4m, current liabilities fell from A$80.9m to A$7.3m, and equity went from a deficiency of A$2.8m to A$29.1m. The cost was heavy dilution: shares on issue rose 161% in FY26, from 636m to 1,661m, and 3.7 times over two years. Mildura was also written down by a further A$19.0m. Its independent fair value under a fair-value-less-costs-to-dispose approach was A$50.6m at 30 June 2026, against A$70.2m a year earlier.

Cash flow. Operating cash burn fell 86%, from A$9.6m to A$1.3m. This was helped by a A$4.9m cut in cash interest and a A$2.3m R&D incentive receipt. The June 2026 quarter showed an operating cash inflow of A$0.24m (Q4 FY26 4C). Year-end cash was only A$0.49m, and the lender's A$250k minimum cash covenant was breached at certain points during the period. Liquidity remains extremely thin.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product Lines

Product line (AUD Mn)FY2025FY2026

Dried flower revenue (AUD Mn)

—7.7

Oils revenue (AUD Mn)

—0.5

Products total (AUD Mn)

11.1388.551

Services, contract packing (AUD Mn)

0.1620.012

Total revenue from customer contracts (AUD Mn)

11.3008.563

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Revenue from customer contracts (AUD Mn)

15.3711.308.56

YoY revenue growth (%)

11.5-26.5-24.2

Operating result before finance costs, impairment and debt gain (AUD Mn)

-24.52-16.38-10.93

Operating margin (%)

-159.5-145.0-127.7

Normalised EBITDA, company definition (AUD Mn)

—-5.0-3.7

Pre-tax income (AUD Mn)

-51.24-22.3520.30

Segment Revenue

AUD KH1 FY26H2 FY26FY26

Revenue from customer contracts

4,5214,0428,563

Administration and corporate costs

(2,044)(1,955)(3,999)

Direct production costs (ex write-down)

(1,101)(821)(1,922)

Employee costs

(3,869)(3,238)(7,107)

Operating costs before D&A, write-down and R&D

(7,014)(6,014)(13,028)

Inventory write-down

—(1,737)(1,737)

Depreciation and amortisation

(3,642)(2,215)(5,857)

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from customer contracts (AUD Mn)

6.4113.7815.3711.308.56

Other income incl. R&D incentive and grants (AUD Mn)

4.836.862.991.951.09

Revenue less direct production costs (AUD Mn)

———3.204.90

Operating income before finance costs and one-offs (AUD Mn)

-24.25-29.73-24.52-16.38-10.93

Depreciation and amortisation (AUD Mn)

4.8011.9611.047.445.86

EBITDA, derived as operating income plus D&A (AUD Mn)

-19.45-17.77-13.48-8.94-5.07

EBITDA normalised, company definition (AUD Mn)

———-5.0-3.7

Interest / finance costs (AUD Mn)

1.833.166.826.005.12

Pre-tax income (AUD Mn)

-26.47-33.79-51.24-22.3520.30

Net income (AUD Mn)

-26.47-33.79-51.24-22.3520.30

EPS basic (A$ cents)

———-4.231.62

EPS diluted (A$ cents)

———-4.231.62

Dividends per share (A$ cents)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue less direct production costs margin (%)

———28.357.3

Operating margin (%)

-378.3-215.7-159.5-145.0-127.7

EBITDA margin, derived (%)

-303.4-129.0-87.7-79.1-59.2

Net margin (%)

-413.0-245.2-333.4-197.8237.1

Key Financials

Item (AUD Mn)FY2025FY2026

Statutory NPAT

-22.320.3

Gain on bank debt forgiveness

055.3

Gain on settlement of trade creditors

00.3

Impairment of Mildura property, plant and equipment

0-19.0

Inventory write-down

-3.9-1.7

Normalised loss after tax (company)

-18.5-14.7

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

139.66129.4792.7778.7951.99

Cash and equivalents (AUD Mn)

1.910.771.640.010.49

Inventories (AUD Mn)

10.6711.418.514.344.58

Property, plant and equipment (AUD Mn)

118.21107.4076.4469.1744.69

Goodwill and intangibles (AUD Mn)

1.460.220.040.010.00

Short-term debt incl. current borrowings, leases and notes (AUD Mn)

3.8015.2972.0575.381.03

Long-term debt incl. leases and notes (AUD Mn)

43.3645.670.420.4715.36

Total debt (AUD Mn)

47.1760.9772.4775.8416.39

Net debt (AUD Mn)

45.2560.2070.8375.8315.90

Total equity (AUD Mn)

84.9059.2613.92-2.7829.06

Working capital (AUD Mn)

7.87-3.19-61.99-71.34-0.06

Shares on issue (millions)

351.36388.61445.85636.181,660.59

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

-20.43-22.84-15.19-9.64-1.33

Capital expenditure (AUD Mn)

-45.16-3.10-2.51-0.16-0.41

Free cash flow (AUD Mn)

-65.60-25.94-17.69-9.80-1.74

Proceeds from share issues, net (AUD Mn)

17.928.184.462.838.28

Net debt issued / (repaid) (AUD Mn)

46.4913.8010.315.35-6.06

Cash interest paid (AUD Mn)

——4.575.460.54

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on ending equity (%)

-31.2-57.0-368.1—69.9

ROA on ending assets (%)

-19.0-26.1-55.2-28.439.0

ROIC, operating income / (equity + net debt) (%)

-18.6-24.9-28.9-22.4-24.3

Current ratio (x)

1.700.870.210.120.99

Debt to equity (x)

0.561.035.21—0.56

Interest coverage, operating income / finance costs (x)

-13.3-9.4-3.6-2.7-2.1

Asset turnover, revenue / ending assets (x)

0.0460.1060.1660.1430.165

Revenue by Region and Revenue by Region (%)

Region (AUD Mn)FY2025FY2026

Australia, derived residual (AUD Mn)

11.247.19

United Kingdom (AUD Mn)

01.00

New Zealand (AUD Mn)

0.060.36

Total international (AUD Mn)

0.061.37

International share of revenue (%)

0.516.0

Share Price History

DatePrice (AUD)Context / source

3 May 2017

0.300

IPO price

26 May 2020

1.140

Export agreements (FNN)

31 Oct – 3 Dec 2025

0.0115

Placement price

8 Jan 2026

0.010

Fintel

16 Mar 2026

0.007

Convertible announcement

30 Jun 2026

0.002

Price at release of redemption notice; 52-week low area

31 Jul 2026

0.003

StockAnalysis

16 Sep 2026

0.005

StockAnalysis (latest verified)

Valuation Snapshot

MultipleValueComment

Market capitalisation

About A$8.3m

1,660.6m shares

Enterprise value

About A$24.2m

Market cap + A$16.39m debt − A$0.49m cash. About A$26m including the A$2m July 2026 facility increase, partly used to redeem the A$0.55m notes.

P/E (statutory)

About 0.3x

Distorted by the A$55.3m gain; not meaningful

P/E (normalised)

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

About 2.8x

On FY26 revenue of A$8.56m

P/B

About 0.29x

On net assets of A$29.1m; NTA of A$0.0175 per share against a A$0.005 price

Capital Instruments

InstrumentAmount (AUD Mn)RateMaturity

Private credit refinancing loan

15.36 carrying at 30 Jun 2026, plus up to 2.0 added Jul 2026

12.5% (9.5% cash + 3.0% PIK)

31 Dec 2027

R&D tax incentive advance

0.4716%

31 Oct 2026 (repaid from the R&D refund)

Insurance premium funding

0.01—

31 Jul 2026

Chattel mortgages

0.011—

Short-term

Convertible notes

0 (redeemed 3 Jul 2026)

——

Analyst Conclusions

Management guidance

Management has given no quantitative FY27 guidance. Its qualitative outlook is:

  • a "very strong start", with July revenue well ahead of the prior year and export revenue strong into August;

  • a material increase in FY27 production volume and operating leverage, based on forward orders;

  • an FY27 cost base anchored on the H2 FY26 run-rate of about A$12m (operating costs before depreciation), plus a full year of lower interest.

There are no consensus estimates.

Bull case

  1. Asset value far above the market price. The independent fair value of Mildura (A$50.6m) and net assets (A$29.1m) compare with a market capitalisation of about A$8m (0.29x book). A trade sale or partnership with a global operator seeking EU-GMP-capable capacity could re-rate the equity sharply.

  2. Operating leverage at near-breakeven cash flow. With costs reset to about A$12m a year and Q4 FY26 operating cash flow already positive (A$0.24m), each extra tonne of export flower falls largely to EBITDA. The facility can produce well above 4.6 tonnes.

  3. Export inflection. The UK went from zero to A$1.0m in one year; German licences are in hand; and Germany is Europe's fastest-growing medical cannabis market (LGP sold A$5.5m into Germany in one quarter). Exports were 16% of FY26 revenue and are reportedly accelerating.

Bear case

  1. Revenue is still shrinking and guidance has been unreliable. FY26 revenue (A$8.56m) fell 24% and came in about 50% below the October 2025 target. The EBITDA-positive target became a A$3.7m loss.

  2. Fragile liquidity and refinancing risk. Cash was A$0.49m at year end, covenant breaches needed waivers, and expensive 12.5% secured debt of about A$17m matures in December 2027. The going-concern emphasis of matter persists, and further equity raises at near-zero prices would add to dilution of more than 270% over two years.

  3. Governance and execution gaps. There is no permanent CEO, the interim Executive Chair has a six-month term, and CEO turnover has been high (three CEOs since 2022). Customer concentration (three customers each above 10%) and single-site risk compound the problem.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Oct 2026Receipt of the A$0.62m R&D refund and repayment of the A$0.47m R&D loan
Late Oct 2026Q1 FY27 Activities Report / 4C: validation of the "very strong start" claim, export revenue and cash flow
Nov 20262026 AGM: auditor ratification, remuneration vote, possible board renewal; expiry or extension of the Executive Chair's six-month term (from 6 May 2026)
H2 CY2026Permanent CEO appointment
Any timeOutcome of the strategic partnering / M&A review (unconfirmed)
FY27First German export revenue; additional EU market approvals; non-irradiated flower specification
FY27Production volume against the 4.6-tonne FY26 base; capacity utilisation
Feb 20271H FY27 results: first half on the fully reset cost base
OngoingCovenant compliance and refinancing progress ahead of Dec 2027

Analyst verdict

Cann Group in October 2026 is a balance-sheet survivor with an operating business that has not yet earned its place.

The December 2025 NAB settlement was a decisive event for shareholders. It extinguished A$55.3m of debt, moved equity from a deficiency to A$29.1m, and cut cash interest by almost A$5m a year. Combined with a 34% reduction in operating costs, it brought the operating cash burn of a company that lost more than A$130m between FY2022 and FY2025 down to near breakeven. By any measure, that is a credible restructuring.

The commercial picture is weaker:

  • Revenue has fallen for two years running, to A$8.56m, which is below the scale of FY2023.

  • The FY26 targets presented to investors during the recapitalisation, roughly A$17m of revenue and positive EBITDA, were missed by wide margins.

  • The CEO who led the turnaround left within five months of completing it.

  • The facility ran at roughly half capacity, and domestic price pressure shows no clear sign of easing.

The equity is therefore best viewed as an option on two outcomes:

  1. Organic export conversion. The UK, and potentially Germany, would need to absorb meaningfully more Mildura output at better prices than domestic bulk.

  2. Strategic monetisation of a GMP-certified facility independently valued at about six times the market capitalisation.

The first outcome needs evidence over successive quarters, starting with the Q1 FY27 4C. The second depends on buyer appetite in a sector that is consolidating but still capital-constrained. Downside risks are substantial: thin cash, covenant fragility, 12.5% secured debt maturing in December 2027, a going-concern emphasis of matter and a history of dilutive funding. These mean that failure on either outcome would likely be resolved through further heavily dilutive capital or lender-led action.

On balance, Cann is a high-risk, special-situation exposure. Its discount to book is justified by execution and financing risk rather than mispricing alone. The most important near-term tests are:

  • Q1 FY27 export revenue and cash flow;

  • the appointment of a permanent CEO;

  • any concrete strategic transaction.

Each should be monitored closely before the turnaround thesis can be considered de-risked.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Mike Ryan

Executive Chairman (interim)

Chair since 28 Nov 2025; Executive Chair since 6 May 2026 (six-month initial term, extendable)

More than 40 years in financial services. Former head of equities at Shaw and Partners (6 years); 12 years at Goldman Sachs as executive director; executive director and head of distribution at Morgan Stanley. Chair of Sequoia Financial Group (ASX:SEQ); director of Energy One (ASX:EOL) and PM Capital Global Opportunities Fund (ASX:PFG).

Steven Notaro

Company Secretary

——

“—” = not publicly disclosed.

Board of Directors

NameRoleBackgroundIndependence

Mike Ryan

Executive Chairman

See above

Not independent while executive

Doug Rathbone

Non-executive director (Chair until Nov 2025 AGM)

Former MD and CEO of Nufarm (about 40 years). Chairman of Rathbone Wine Group; director of Cotton Seed Distributors, Leaf Resources and AgBiTech; former CSIRO director.

Presumed independent

Peter Kopanidis

Non-executive director

More than 30 years in finance: investor relations, treasury and corporate finance at Medibank, Telstra, Treasury Wine Estates and Foster's. Owner of Petra Investor Relations & Debt Advisory. Chartered Accountant; ex-KPMG.

Presumed independent

Julian Chick

Non-executive director (per Dec 2024 insider trades)

Not detailed in the sources reviewed

—

Robert Barnes

Non-executive director (per Dec 2024 insider trades)

Not detailed in the sources reviewed

—

Major Shareholders

HolderShares%Date of noticeSource

Noble Investments Superannuation Fund Pty Ltd

215,004,00513.54

16 Jan 2026

Market Index

Regal Funds Management Pty Ltd and associates

96,634,8275.89

22 May 2026

Market Index; became substantial 4 Dec 2025

Ryan Prue Pty Ltd

18,450,0001.16

Mar 2026

—

Adsd Soodin Holdings Pty Ltd

17,721,4901.12

Mar 2026

Simply Wall St

Gary Burg

15,098,5610.95

Mar 2026

Simply Wall St

Philip Robert Jacobsen

13,892,6740.87

Mar 2026

Simply Wall St

Competitive Landscape

Key Competitors

CompetitorType / segment overlapPositioning relative to Cann

Little Green Pharma (ASX:LGP)

Vertically integrated Australian and Danish producer; oils, flower, vapes; Europe

Far larger and profitable at the adjusted EBITDA level; ahead on European distribution

Canopy Growth (TSX: WEED / Nasdaq: CGC)

Global cannabis; international medical exports

Global scale; competes in the UK, Germany and Australian import channels

Tilray Brands (Nasdaq: TLRY)

Global medical cannabis, EU GMP production (Portugal, Germany)

—

Aurora Cannabis (TSX/Nasdaq: ACB)

Global medical cannabis; Australian and EU presence

—

Organigram (Nasdaq: OGI)

Canadian LP exporting to Australia and the EU

—

Curaleaf International

European medical cannabis (UK, Germany)

—

Cannatrek (private, Australia)

Domestic cultivator and brands

Direct domestic flower competitor

Australian Natural Therapeutics Group (private)

Domestic cultivator

Direct domestic competitor

Montu / Alternaleaf (private)

Telehealth prescribing and distribution platform

Controls patient demand; channel and customer as well as competitor

Vitura Health (ASX:VIT)

Distribution and telehealth platform

—

Bod Science (ASX:BOD)

CBD and medicinal cannabis products

—

Imported Canadian, Portuguese and Colombian flower

Low-cost import supply

The main source of domestic price compression

Peer Comparison FY2026

MetricCann Group (FY Jun-26)Little Green Pharma (FY Mar-26)Canopy Growth (FY Mar-26)

Revenue

A$8.56m

A$42.49m

C$284.6m (net)

Revenue growth YoY

-24.2%+15.3%+6%

Adjusted EBITDA

-A$3.7m (normalised)

+A$6.49m

-C$20.2m

Adjusted EBITDA margin

-43%+15%-7%

Statutory net result

+A$20.3m (one-offs) / -A$14.7m normalised

-A$1.41m

Net loss narrowed 49% (continuing operations)

R&D intensity

About 0% (FY26 net benefit)

About 0.1% (A$0.05m)

—

Operating cash flow

-A$1.33m

+A$0.04m

—

Recent Developments

A Kalkine Media article dated 13 Jul 2026 refers to new UK/EU supply agreements.

Company Snapshot

2014

Founded

Koorlong, Australia

Headquarters

SWOT Analysis

Strengths

  • GMP-certified scale asset. Mildura was built for about A$115–120m and designed for more than 12,500kg a year, and its FY26 independent fair value was A$50.6m (Appendix 4E Note 6). That is about six times the market capitalisation.
  • De-levered balance sheet. Total debt fell from A$75.8m to A$16.4m; current liabilities from A$80.9m to A$7.3m; and equity rose to A$29.1m (Appendix 4E FY26).
  • Proven cost cuts. Operating costs before depreciation fell 34% to A$14.7m, with an H2 run-rate of about A$12m (FY26 Results).
  • Cash burn largely eliminated. Operating cash outflow fell from A$9.64m to A$1.33m (-86%), and the June 2026 quarter showed a A$0.24m inflow (Q4 FY26 4C).
  • First-mover licence and genetics. Cann held Australia's first research and cultivation licences (Feb/Mar 2017) and has proprietary cultivars in production (AGM 2025).
  • Export validation. First-year UK revenue was A$1.0m, international sales reached 16% of revenue, and German AMRadV licences are in hand (FY26 Results; Q3 4C).

Weaknesses

  • Shrinking revenue. Revenue fell 24% to A$8.56m, the second consecutive decline, and is down 44% from the FY24 peak.
  • Persistent normalised losses. The normalised loss after tax was A$14.7m and normalised EBITDA was -A$3.7m in FY26.
  • Guidance credibility. The October 2025 target of about A$17m revenue and positive EBITDA was missed by about 50% and A$4m respectively.
  • Under-utilisation. Mildura produced 4.6 tonnes, at near half of fitted capacity, against a 7.7-tonne budget.
  • Thin liquidity and covenant stress. Year-end cash was A$0.49m. The shareholder-funds covenant was breached and waived, and the minimum cash covenant was breached at points in the year.
  • Leadership gap. There has been no permanent CEO since 5 May 2026; the Chair is acting in an executive role.

Opportunities

  • German / EU export scale-up under AMRadV licences, as Europe increasingly mandates GMP flower.
  • Strategic sale or partnership. Management has flagged M&A in a consolidating sector, and the asset value is well above market capitalisation.
  • Operating leverage. About A$0.8m a year in profit per A$0.10/gram price increase at 8 tonnes (AGM 2025).
  • TGA regulatory tightening, which would favour GMP domestic producers.
  • Brand mix shift to Mallee Bloom and own-grown Botanitech, whose own-grown revenue more than doubled in FY25.
  • Contract packing and white-label services to fill spare GMP packing capacity.

Threats

  • Domestic price compression from imports and oversupply, which management cites as the main driver of the FY26 revenue decline.
  • Refinancing risk. The A$15.4m facility, plus the A$2m added in July 2026, matures on 31 Dec 2027 at 12.5%.
  • Dilution. Shares rose from 446m (FY24) to 1,661m (FY26); 198m options were outstanding at 30 Jun 2026; and the A$15m convertible facility remains notionally available.
  • Customer concentration. Three customers each exceed 10% of revenue.
  • Further impairment. Cumulative impairments on Mildura are A$39.1m (land and buildings A$27.2m; plant A$11.9m).
  • Regulatory change in Australian telehealth prescribing or EU import rules.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Apr 2025Private placement of 41.9m shares at about A$0.017, with 49.4m attaching options at A$0.03Emergency working capital
24 Apr & 12 Jun 2025R&D tax incentive loan advances totalling A$1.18mLiquidity bridge
Jun 2025Short-term finance for Industrial Special Risks insuranceLiquidity strain indicator
30 Jun 2025FY25 year-end: cash A$10k; net asset deficiency A$2.78m; borrowings of A$74.9m all currentPeak distress
Aug 2025First EBITDA-positive month (management)Operational proof point (not repeated in full-year results)
Jul–Sep 2025Repeated note conversions (about 67m shares)Ongoing dilution
Sep–Oct 2025Capital raising presentation: about A$17m FY26 revenue and EBITDA-positive targetsGuidance later withdrawn
27 Oct 2025Debt restructure and new private credit loan arrangements announcedRecapitalisation launched
Oct 2025Gummies launchedProduct extension
31 Oct 2025Placement tranche 1: 120.4m shares at A$0.0115Equity
24 Nov & 3 Dec 2025Share purchase plan and shortfall: 250m shares at A$0.010 (A$2.5m)Retail support
28 Nov 2025AGM: lender options approved; Mike Ryan becomes ChairGovernance change
3 Dec 2025Placement tranche 2: 444.8m shares at A$0.0115Equity
4–8 Dec 2025Regal Funds Management becomes a substantial holderNew institutional holder
11 Dec 2025Private credit refinancing facility executed (A$14.75m)Funding
15 Dec 2025NAB settlement completed: A$70.6m discharged for A$15.3mTransformational
24 Dec 2025933.6m options granted, of which 830.2m expired unexercised on 15 Jun 2026Overhang created, then expired
6–16 Jan 2026Noble Investments Superannuation Fund becomes the largest holder (13.54%)Register change
27 Feb 20261H FY26 results: NPAT A$26.4m; EBITDA breakeven targeted for H2Target subsequently missed
16–18 Mar 2026A$750k Obsidian convertible (third purchase), capped at 195m sharesRenewed dilution risk
Q3 FY26First UK flower export; German AMRadV licencesExport milestone
29 Apr 2026Q3 4C: revenue A$2.32m (+42% QoQ); FY26 guidance cut to A$9.2–10.0m; M&A exploration flaggedGuidance downgrade
5 May 2026CEO and MD Pilcher resigns; Ryan becomes interim Executive ChairmanLeadership instability
26 May 2026Change in substantial holding (Regal at 5.89%)Register
15 Jun 2026830.2m December 2025 options lapseOverhang removed
29 Jun 2026A substantial holder ceases (identity not confirmed here)Register
30 Jun 2026Early redemption of remaining 350,000 notes agreed (US$402.5k face; net US$363.7k)Removes toxic convertible
3 Jul 2026Private credit facility increased by A$2m to fund the redemptionDebt up, dilution risk down
13 Jul 2026Auditor change to Stannards AuditAdministrative
30 Jul 2026Q4 4C: operating cash inflow A$0.24m; Mallee Bloom SKUs; German export pathwayNear cash breakeven
31 Aug 2026FY26 results and Appendix 4EStatutory profit on one-offs; going-concern emphasis expected
25 Sep 2026FY26 Annual Report lodgedAudited accounts
Oct 2026 (expected)R&D refund of about A$0.62m to repay the A$0.47m R&D loanMinor liquidity

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from customer contracts rose from AUD 6.4 Mn in FY2022 to AUD 8.6 Mn in FY2026.
Cann Group Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from customer contracts6.413.815.411.38.6
Revenue less direct production costs———3.24.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Cann Group Limited, Appendix 4E Preliminary Final Report FY2026 (31 Aug 2026) (bulletin.webull.com)
  2. Cann Group Limited, FY26 Results ASX Announcement (31 Aug 2026) (bulletin.webull.com)
  3. Cann Group Limited, 1H FY26 Results (27 Feb 2026) (bulletin.webull.com)
  4. Cann Group Limited, 2025 AGM / Capital Raising Presentation (28 Nov 2025) (bulletin.webull.com)
  5. Cann Group Limited, Leadership Transition (5 May 2026) (announcements.asx.com.au)
  6. Cann Group Limited, Early Redemption of Convertible Notes (30 Jun 2026) (bulletin.webull.com)
  7. Cann Group Limited, Increase to Private Credit Loan Facility (3 Jul 2026) (bulletin.webull.com)
  8. Cann Group Limited, Change of Auditor (13 Jul 2026) (bulletin.webull.com)
  9. InvestSMART summaries of Q3 FY26 4C, Q4 FY26 4C and the Mar 2026 convertible (investsmart.com.au)
  10. StockAnalysis.com (S&P Global Market Intelligence data), CAN income statement, balance sheet and cash flow (stockanalysis.com)
  11. Market Index, CAN substantial shareholders (marketindex.com.au)
  12. Simply Wall St, CNGGF ownership (simplywall.st)
  13. Aurora Cannabis press releases (Mar and Dec 2017), via New Cannabis Ventures (newcannabisventures.com)
  14. Stockhead, Cann Group history and iuvo investment · stockhead.com.au
  15. Business News Australia, CEO transitions and Southern facility sale (businessnewsaus.com.au)
  16. MJBizDaily, 2024 CEO resignation and ASX suspension (mjbizdaily.com)
  17. La Trobe University, Cann Group partnership case study (latr-dev.matrix.squiz.cloud)
  18. NZX / Rua Bioscience, Germany export via Cann partnership (28 Jun 2022) (nzx.com)
  19. Finance News Network, 2020 export agreements (finnewsnetwork.com.au)
  20. TipRanks, Chemist Warehouse agreements; CEO permanent appointment (tipranks.com)
  21. Little Green Pharma, Appendix 4E FY2026 (announcements.asx.com.au)
  22. Canopy Growth, FY2026 results (15 Jun 2026) (canopygrowth.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.